Oral presentations

ESCORT-1st: A Randomized, Double-blink, Placebo-controlled, Phase 3 Trial of Camrelizumab Plus Chemotherapy vs Chemotherapy in Patients With Untreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with advanced solid tumors

Combination of Famitinib with Camrelizumab plus Nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study

Captain-1st: Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicenter, randomized, double-blind, phase 3 trial

Dalpiciclib plus fulvestrant versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): a multicenter, randomized, phase 3 study